Lab Med Online.  2020 Jan;10(1):10-24. 10.3343/lmo.2020.10.1.10.

Revision of Laboratory Testing Guidelines for Initial Diagnosis of Hematologic Neoplasms

• Kim IS
• Lee JY
• Kong SY
• Lee ST
• Huh J
• Nam MH
• Kim M
• Cho YU
• Huh HJ
• Song J
• Park H

• KMID: 2466761
• DOI: http://doi.org/10.3343/lmo.2020.10.1.10

Abstract

The standardization committee of the Korean Society for Laboratory Hematology revised laboratory testing guidelines in order that hematologic neoplasms could be diagnosed according to the revised 4th edition of WHO classification of tumors of haematopoietic and lymphoid tissues. The new guidelines were revised based on an extensive review of international guidelines that included the National Comprehensive Cancer Network Guidelines, and European LeukemiaNet recommendations that are based on the revised WHO classification. We expect that the newly revised guidelines will improve clinical decisions, standardize laboratory tests, and enhance the development of new molecular technologies that are integrated into diagnostic algorithms via ongoing consensus initiatives.

Keyword

Hematologic neoplasms; Diagnosis; Laboratory testing; Guidelines

MeSH Terms

Classification
Consensus
Diagnosis*
Hematologic Neoplasms*
Hematology
Lymphoid Tissue

Reference

1. Swerdlow SH, Campo E, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: IARC;2017.

2. Lee JY, Kim HK, Huh J, Kim M, Kong SY, Cho YW, et al. Test guidelines for initial diagnosis of hematologic neoplasms. Lab Med Online. 2016; 6:1–7.

3. Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, et al. Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018; 16:1108–1135.

4. Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, et al. NCCN guidelines insights: Myeloproliferative neoplasms, version 2.2018. J Natl Compr Canc Netw. 2017; 15:1193–1207.

5. Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, et al. Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017; 15:60–87.

6. O’Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, et al. Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017; 15:926–957.

7. Brown PA, Shah B, Fathi A, Wieduwilt M, Advani A, Aoun P, et al. NCCN guidelines insights: Acute lymphoblastic leukemia, version 1.2017. J Natl Compr Canc Netw. 2017; 15:1091–1102.

8. Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, et al. NCCN guidelines insights: Multiple myeloma, version 3.2018. J Natl Compr Canc Netw. 2018; 16:11–20.

9. Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, et al. NCCN guidelines insights: Non-Hodgkin's lymphomas, version 3.2016. J Natl Compr Canc Netw. 2016; 14:1067–1079.

10. Horwitz SM, Ansell SM, Ai WZ, Barnes J, Barta SK, Choi M, et al. NCCN guidelines insights: T-cell lymphomas, version 2.2018. J Natl Compr Canc Netw. 2018; 16:123–135.

11. Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Armand P, et al. NCCN guidelines insights: Hodgkin lymphoma, version 1.2018. J Natl Compr Canc Netw. 2018; 16:245–254.

12. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129:424–447.

13. Heidel FH, Gale RP, Hochhaus A. Managing myeloproliferative neoplasms evidence based on the ELN treatment recommendations 2018. Leukemia. 2018; 32:1055–1056.